🎉 M&A multiples are live!
Check it out!

Alto Neuroscience Valuation Multiples

Discover revenue and EBITDA valuation multiples for Alto Neuroscience and similar public comparables like Pharming, Galapagos, and Benevolent AI.

Alto Neuroscience Overview

About Alto Neuroscience

Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.


Founded

2019

HQ

United States of America
Employees

76

Financials

LTM Revenue n/a

LTM EBITDA -$73.0M

EV

-$95.0M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Alto Neuroscience Financials

Alto Neuroscience has a last 12-month revenue of n/a and a last 12-month EBITDA of -$73.0M.

In the most recent fiscal year, Alto Neuroscience achieved revenue of n/a and an EBITDA of -$59.6M.

Alto Neuroscience expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Alto Neuroscience valuation multiples based on analyst estimates

Alto Neuroscience P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$34.6M -$59.6M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$27.7M -$36.3M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Alto Neuroscience Stock Performance

As of April 15, 2025, Alto Neuroscience's stock price is $2.

Alto Neuroscience has current market cap of $56.3M, and EV of -$95.0M.

See Alto Neuroscience trading valuation data

Alto Neuroscience Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$95.0M $56.3M XXX XXX XXX XXX $-2.53

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Alto Neuroscience Valuation Multiples

As of April 15, 2025, Alto Neuroscience has market cap of $56.3M and EV of -$95.0M.

Alto Neuroscience's trades at n/a LTM EV/Revenue multiple, and 1.3x LTM EBITDA.

Analysts estimate Alto Neuroscience's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Alto Neuroscience and 10K+ public comps

Alto Neuroscience Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$95.0M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 1.6x XXX XXX XXX
P/E -0.9x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 1.9x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Alto Neuroscience Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Alto Neuroscience Valuation Multiples

Alto Neuroscience's NTM/LTM revenue growth is n/a

Alto Neuroscience's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.9M for the same period.

Over next 12 months, Alto Neuroscience's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Alto Neuroscience's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Alto Neuroscience and other 10K+ public comps

Alto Neuroscience Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 72% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $0.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Alto Neuroscience Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Alto Neuroscience M&A and Investment Activity

Alto Neuroscience acquired  XXX companies to date.

Last acquisition by Alto Neuroscience was  XXXXXXXX, XXXXX XXXXX XXXXXX . Alto Neuroscience acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Alto Neuroscience

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Alto Neuroscience

When was Alto Neuroscience founded? Alto Neuroscience was founded in 2019.
Where is Alto Neuroscience headquartered? Alto Neuroscience is headquartered in United States of America.
How many employees does Alto Neuroscience have? As of today, Alto Neuroscience has 76 employees.
Who is the CEO of Alto Neuroscience? Alto Neuroscience's CEO is Dr. Amit Etkin, M.D..
Is Alto Neuroscience publicy listed? Yes, Alto Neuroscience is a public company listed on NYS.
What is the stock symbol of Alto Neuroscience? Alto Neuroscience trades under ANRO ticker.
When did Alto Neuroscience go public? Alto Neuroscience went public in 2024.
Who are competitors of Alto Neuroscience? Similar companies to Alto Neuroscience include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Alto Neuroscience? Alto Neuroscience's current market cap is $56.3M
What is the current EBITDA of Alto Neuroscience? Alto Neuroscience's last 12-month EBITDA is -$73.0M.
What is the current EV/EBITDA multiple of Alto Neuroscience? Current EBITDA multiple of Alto Neuroscience is 1.3x.
Is Alto Neuroscience profitable? Yes, Alto Neuroscience is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.